Agentix (AGTX) Return on Capital Employed (2015 - 2026)
Agentix's (AGTX) quarterly Return on Capital Employed came in at 12.39% in Q1 2026, down 429.0% YoY from 3.77% in Q1 2025, and down 23.0% on a QoQ basis from 16.09% in Q4 2025.
Agentix (AGTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Agentix (AGTX) has 12 years of Return on Capital Employed data on file, last reported at 12.39% in Q1 2026.
- Quarterly Return on Capital Employed fell 429.0% year-over-year to 12.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.39% (down 429.0% YoY) and the FY2026 annual result came in at 12.56%, down 399.0% from the prior year.
- Return on Capital Employed eased to 12.39% in Q1 2026, from 16.09% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 265.9% in Q1 2022 to a low of 8.27% in Q3 2024.
- A 5-year average of 68.79% and a median of 29.12% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 15385 bps — and 2025, when it surged 905 bps.
- Tracing AGTX's Return on Capital Employed over 5 years: stood at 154.6% in 2022, then tumbled by 72 bps to 43.85% in 2023, then sank by 75 bps to 10.86% in 2024, then surged by 48 bps to 16.09% in 2025, then slipped by 23 bps to 12.39% in 2026.
- The last three Return on Capital Employed figures came in at 12.39% (Q1 2026), 16.09% (Q4 2025), and 17.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 9.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.17% |
| Mar 31, 2026 | 12.39% |
| Dec 31, 2025 | 16.09% |
| Sep 30, 2025 | 17.33% |
| Jun 30, 2025 | 17.44% |
| Mar 31, 2025 | 16.68% |
| Dec 31, 2024 | 10.86% |
| Sep 30, 2024 | 8.27% |
| Jun 30, 2024 | 17.96% |
| Mar 31, 2024 | 29.12% |
| Dec 31, 2023 | 43.85% |
| Sep 30, 2023 | 54.56% |
| Jun 30, 2023 | 59.85% |
| Mar 31, 2023 | 59.02% |
| Dec 31, 2022 | 154.60% |
| Sep 30, 2022 | 171.74% |
| Jun 30, 2022 | 213.70% |
| Feb 28, 2022 | 265.90% |
| Nov 30, 2021 | 178.78% |
| Aug 31, 2021 | 242.77% |